Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas

Abstract

Progress in the treatment of adult high-grade gliomas (HGG), including chemoradiation with concurrent and adjuvant temozolomide for glioblastoma, has not translated into significant therapeutic advances for pediatric HGG, where overall survival has plateaued at 15% to 20%, especially when considering specialized pediatric treatment in tertiary care centers, maximal safe neurosurgical resection, optimized delivery of involved field radiation, and improvements in supportive care. However, recent advances in our understanding of pediatric HGG, including the application of next-generation sequencing and DNA methylation profiling, have identified mutations in the histone variant H3.3 and canonical H3.1 genes, respectively. These mutations are relatively specific to neuroanatomic compartments (cortex, midline structures, thalamus, brainstem) and are often associated with other mutations, especially in specific growth factor receptor tyrosine kinases. Targeting epigenetic pathways affected by these histone mutations, alone or in combination with small molecule inhibitors of growth factor receptor signaling pathways, will inform new treatment strategies for pediatric HGG and should be incorporated into novel cooperative group clinical trial designs.

Electronic supplementary material

The online version of this article (doi:10.1007/s13311-017-0514-2) contains supplementary material, which is available to authorized users.

Introduction: Diagnosis and Current Management Strategies

Brain tumors are the most common solid tumors of childhood and have overtaken leukemia as the most common cause of cancer-related mortality in children [1]. Gliomas are tumors arising from the glial cell lineage (astrocytic and /or oligodendroglial) and were historically classified into low (low grade glioma; grade I–II) or high grade [high grade glioma (HGG); grade III–IV] based on histological appearance, biological behavior, and clinical course [2]. The majority of gliomas in children (~50%) are low grade and astrocytic in origin [3]. HGG constitute 3% to 7% of all childhood brain tumors, are less common in children than in adults, and include a heterogeneous group of tumors (anaplastic astrocytoma, glioblastoma (GBM), giant cell GBM, anaplastic oligodendroglioma, etc.) [2]. However, the current revised classification of HGG (and gliomas in general) incorporates characteristic genomic abnormalities (genetic and epigenetic) along with the clinicopathological features (diffuse, cell lineage, anatomical location, etc.) to define distinct tumor entities. This creates the potential for therapies directed against specific clinical and molecular profiles [4]. One such distinct group of tumors occurs primarily in children and is characterized by somatic driver mutations (K27M) in the histone H3 genes (H3F3A, HIST1H3B), midline location (thalamus, brain stem, spinal cord), and diffuse growth pattern on histology [4]. This group is classified as diffuse midline glioma, H3 K27M-mutant and includes previously defined entities such as brain stem gliomas [diffuse intrinsic pontine gliomas (DIPG)]. Another distinct group of diffuse astrocytic tumors seen in children (<20 years) arise in the cerebral hemispheres and are characterized by G34R/V mutations that are restricted to H3F3A (H3.3-G34R/V) [5].

Diffuse midline glioma involving the brain stem constitutes ~12% of all pediatric brain tumors (0–14 years) [1] and > 80% of them are localized to the pons and were formerly known as DIPG [1]. The median age of diagnosis of diffuse midline gliomas is 10 years with pontine tumors occurring earlier (median ~7 years) than the thalamic tumors (median ~11 years) and they occur equally in both sexes [6, 7]. Patients with pontine tumors have rapid onset of symptoms (<2–3 months from the time of diagnosis) and often present with cranial nerve palsies, long tract signs, and ataxia [8]. Thalamic gliomas present with features of raised intracranial pressure, motor weakness/hemiparesis, and gait disturbances [7]. Depending on the location of the hemispheric tumors, the presenting symptoms can vary from developmental delay, failure to thrive, raised intracranial pressure (headache, nausea, vomiting), hemiparesis, seizures, and so on [9]. The diagnosis of diffuse midline pontine gliomas has been based on the clinical presentation with characteristic radiological features and until recently there has been no need for a histological diagnosis in the majority of cases [8]. This “no biopsy” practice has hindered scientific advances in DIPG when compared with other pediatric brain tumors such as medulloblastomas and, to a lesser extent, ependymomas. Diagnostic image-guided stereotactic biopsy of DIPG tumors is now considered to be safe, and provides a means to identify actionable therapeutic targets and risk stratify patients for both therapy and prognosis (as discussed in [8]). The identification of histone mutations (H3.3 and H3.1 K27M) by immunohistochemistry in diffuse midline gliomas may avoid misdiagnosis because of sampling bias due to histological heterogeneity seen in these tumors [10]. Specifically, there is spatial and temporal homogeneity of these histone mutations in the primary and metastatic tumors [11, 12], which is similar to the subgroup stability seen in medulloblastoma across disease sites [13].

Currently, fractionated radiation therapy (RT) directed to the tumor (54–60 Gy, 30 fractions) alleviates symptoms in 60% to 80% of the patients with DIPG and stabilizes disease, albeit on a temporary basis. However, the tumor progresses within the first year of diagnosis with overall survival of 8 to 14 months. Several strategies involving radiation (hyper- or hypofractionation), radiation sensitization, chemotherapy (neoadjuvant, adjuvant, combination with RT), targeted therapy, and agents that alter blood–brain barrier (BBB) permeability have not had any impact on patient survival (event-free and overall survival) [8]. Re-irradiation at the time of tumor progression may add a few months of survival and is tolerated well [8]. The current management of hemispheric diffuse gliomas (Children’s Oncology Group-ACNS0423) includes maximal surgical resection (if possible) followed by involved field RT with concurrent temozolomide (TMZ) and subsequent adjuvant chemotherapy (TMZ with lomustine) [14, 15]. Diffuse midline thalamic gliomas have a poor prognosis similar to DIPG and high-grade histology is associated with short overall survival in these patients [16].

Chromatin Biology and Histone Mutations in Pediatric Diffuse Gliomas

Histone proteins form the core of the nucleosome, which is the fundamental repeating unit of eukaryotic chromatin [17]. Each nucleosome consists of 2 copies of 4 core histone proteins (H3, H4, H2A, and H2B) to form a histone octamer that is wrapped around its radial surface by 147 base pairs of DNA (Fig. 1) [18]. Histone H3 has three isoforms (H3.1, H3.2, and H3.3) with only limited differences: H3.1 differs from H3.2 by a single amino acid, while H3.3 differs at 4 positions [17]. Histones H3.1 and 3.2 are the canonical H3 forms, and are incorporated into DNA during S phase by chromatin assembly factor 1 and at DNA repair sites in a replication-dependent manner [17]. In contrast, incorporation of the noncanonical histone H3.3 is independent of replication and can occur in nondividing cells [17]. H3.3 is deposited at actively transcribed and heterochromatic subtelomeric regions by the DAXX/ATRX complex and at pericentromeric regions by the HIRA chaperone (reviewed in [17]). Histone H3.1 is encoded by 10 genes clustered on chromosome 6 and H3.2 is encoded by 3 genes (HIST2H3A, HIST2H3C, and HIST2H3D) on chromosome 1 [17]. The noncanonical histone H3.3 is encoded by 2 isolated genes (H3F3A on chromosome 1 and H3F3B on chromosome 17) that produce identical proteins [17].

Fig. 1.

An overview of epigenetic targets in pediatric high-grade gliomas. The nucleosome is depicted as an octamer of core histone (H2A, H2B, H3, and H4). Glioma-associated mutations occurring in canonical histone H3 (H3.1) or the H3.3 variant are indicated and the H3K27M to reduce levels of histone H3-lysine 27 methylation (H3K27me3). Representative histone modifications (methylation and acetylation) are shown on the N-terminal histone H3 tails, together with DNA methylation (me), which is catalyzed by DNA methyltransferase (DNMT) enzymes. These modifications are: 1) placed by histone methyltransferase (HMT) or histone acetyltransferase (HAT) writers (W); 2) bound by readers (R) containing a chromo- or bromodomain that can recruit additional regulatory proteins; and 3) removed by erasers (E) that include histone demethylase (HDM) or histone deacetylase (HDAC) enzymes. Therapeutics undergoing preclinical or clinical testing that target these activities are indicated, as well as those that inhibit DNA methylation. Combinations with either chemotherapy or radiation therapy (yellow icons) are noted in the text

Histone proteins undergo a wide range of covalent modifications predominantly at the amino (N-) and carboxy (C-) terminal tails, including acetylation, methylation, phosphorylation, adenosine diphosphate ribosylation, and ubiquitylation to name a few [18]. These modifications (colloquially referred to as histone marks) are mediated by writers, erasers, and readers.

Writers are enzymes that modify specific substrates by adding chemical groups (i.e., histone acetyl transferases, histone methyl transferases). Erasers are proteins that remove specific groups [i.e., histone deacetylases (HDACs), histone demethylases]. Readers are proteins that recognize specific histone modifications (i.e., histone acetyl groups by bromodomains, histone methyl groups by chromodomains) [18]. Histone modifications are associated with various nuclear functions, such as gene transcription or silencing, mitosis, DNA replication/repair, and chromatin assembly [17]. For instance, acetylation of histone tails results in a relaxed chromatin structure (euchromatin) that facilitates gene transcription, whereas methylation can be associated with a range of functions depending on the residue modified and number of groups added, which can involve mono- (me¹), di- (me²), or trimethylation (me³) [18]. One such important mark is the trimethylation of histone H3 on lysine 27 (H3K27me3), which is placed by the enhancer of zeste homolog-1/2 writers (EZH1/2) and erased by the JMJD3/KDM6B and UTX/KDM6A enzymes to control stem cell and oncogenic gene expression programs [19, 20].

Over the past several years, chromatin defects have become central to the pathogenesis of HGG in children when compared with adults. Next-generation sequencing of pediatric HGGs has identified recurrent somatic “oncohistone” mutations in H3 histone genes (summarized in Table 1) [5, 6, 10, 17, 49, 55–57]. These mutations include: 1) missense mutations in H3F3A that lead to substitution of lysine-27 with methionine (H3.3-K27M) and, on rare occasions, to isoleucine (H3.3-K27I) in diffuse midline gliomas; 2) glycine 34 to arginine (H3.3-G34R) or, less frequently, glycine 34 to valine (H3.3-G34V) substitutions in cortical tumors; and 3) mutations in the canonical histone H3 genes HIST1H3B and HIST1H3C that encode H3.1-K27M or H3.2-K27M, respectively, in tumors of the pontine region. Strikingly, these mutations are very location specific and occur in distinct age groups (as discussed below), as well as having considerable diagnostic, therapeutic, and prognostic significance (Table 1) [5, 10, 49, 55].

Table 1.

Candidate epigenetic and genetic targets in the treatment of pediatric diffuse high-grade gliomas

Location	Subtype	Clinical features	Epigenetic mutations	Targetable genetic alterations	Specific therapies	Comments	Reference(s)
1) Cerebral cortex
	1) G34R/V	1) Age: 18 yr (range 9–42 yr) 2) M > F 3) median survival 24 mo	1) H3F3A (G34R/V) (12–14%) 2) SETD2 (LOF)(15%) 3) ATRX-LOE (100%)	a) NTRK1/2/3 mutations (10%) b) MYCN (upregulation)	a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762. b) N-MYC destabilization: AURKA inhibitors MK5108, MLN8054, MLN8237. c) NTRK inhibitors: lestaurtinib (NTRK2), AZ64 (pan-NTRK inhibitor) d) CHK-1 inhibitors: SB21807, TCS2312	a) BET bromodomain inhibitors may be useful in genetically diverse HGG b) NTRK mutations are fusion genes, seen more commonly in children < 3 yr	[5, 21–30]
	2) IDH	1) Age: 40 yr (range 5–71 yr) 2) M = F 3) Median survival (OS) 27 mo	DNMT-1	a) IDH1-R132H (0–16%) (b) IDH2-R140Q	a) IDH1 inhibitors: AG-120, IDH305 b) IDH2 inhibitors: AG-221 c) IDH1/2 inhibitors: AG-881 d) DNMT1 inhibitors: 5-azaC, 5-azadC	a) Frontal lobe tumors b) IDH1 mutations described in children < 10 yr c) NCT02073994, NCT02381886, NCT02273739, NCT02481154	[5, 31–36]
b) Midline
	1) Thalamus/ basal ganglia	1) Age: 11 yr (range 5–23 yr) 2) M > F 3) Median survival 12 mo	a) H3F3A(K27M) (50%)	a) FGFR1 b) BRAF-V600E (10–25%) c) MET (10%)	a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762 b) Histone demethylase inhibitors: JMJD3 inhibitor: GSKJ4, LSD1 inhibitor: tranylcypromine c) HDACi: vorinostat, panobinostat d) FGFR1 inhibitors e) BRAF-V600E inhibitors: vemurafenib, dabrafenib. f) MET inhibitors: crizotinib	a) PBTC-047 b) Combination of inhibitors may increase synergy c) FGFR1—gain-of-function mutations d) BGJ398 (NCT-01975701) e) MET mutations are fusion genes f) LSD1/FGFR1 Inhibitors need further in vitro and in vivo validation in HGG	[5, 16, 21, 24, 30, 37–48]
	2) Pons
	K27M-H3.3	1) Age: 7 yr (median) 2) M = F 3) Median survival 9 mo	a) H3F3A (K27M)80% b) H3F3A(K27I)	a) PDGFRA (amp/ mut/del) (40%) b) MET (10%)	a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762 b) Histone demethylase inhibitors: JMJD3 inhibitor: GSKJ4, LSD1 inhibitor: tranylcypromine c) HDACi: vorinostat, panobinostat. d) PDGFRA inhibitors: imatinib, dasatinib, nilotinib, etc. e) Menin inhibitors: MI-2 f) MET inhibitors: crizotinib	a) Dasatinib and nilotinib have better CNS penetration than imatinib b) MET mutations are fusion genes and crizotinib is in clinical trials	[5, 6, 10, 17, 21, 24, 30, 38–54]
	K27M-H3.1	1) Age: 5 yr (median) 2) M > F 3) Median survival 15 mo	a) HIST1H3B/HIST1H3C (20%)	a) ACVR1 (20–22%)	a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762 b) Histone demethylase inhibitors: JMJD3 inhibitor: GSKJ4, LSD1 inhibitor: tranylcypromine c) HDACi: vorinostat, panobinostat d) ACVR1/ALK2 inhibitors: lestaurtinib, K02288, LDN193189	a) LSD1/ACVR1 inhibitors need further in vitro and in vivo validation in HGG	[5, 6, 10, 24, 30, 38–41, 49, 55–61]
	K27M-WT	1) Age: 6 yr 2) F > M 3) Median survival 12 mo		a) MYCN (upregulation)	a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762. b) MYCN destabilization: AURKA inhibitors MK5108, MLN8054, MLN8237		[6, 10, 21–24, 27–30, 49, 55]
	3) Spinal cord/cerebellum	1) Age: 25 yr (4–41 yr) 2) M > F	a) H3F3A (K27M)(53%) b) ATRX -LOE (57%)		a) BET bromodomain inhibitors: JQ-1, I-BET151, I-BET762. b) Histone demethylase inhibitors: JMJD3 inhibitor: GSKJ4, LSD1 inhibitor: tranylcypromine c) HDACi: vorinostat, panobinostat	a) LSD1 inhibitors need further in vitro and in vivo validation in HGG	[5, 24, 30, 38–41, 62, 63]

M = male; F = female; MYCN = V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog; BET = bromodomain and extraterminal domain; AURKA = aurora kinase A; NTRK = neurotrophin receptor; CHK-1 = Checkpoint kinase 1, a serine/threonine protein kinase; HGG = high-grade glioma; IDH = isocitrate dehydrogenase; OS = Overall Survival; DNMT-1 = DNA methyltransferase 1; IDH1 = isocitrate dehydrogenase 1; 5-azaC = 5-azacytidine; 5-azadC = 5-aza-deoxycytidine; FGFR1 = fibroblast growth factor receptor 1; MET = c-Met, a tyrosine-kinase also known as hepatocyte growth factor receptor; LSD1 = lysine-specific demethylase 1; HDACi = histone deacetylase inhibitor; PDGFR = platelet-derived growth factor receptor; PDGFR = PDGFR alpha; MI-2 = menin inhibitor 2; CNS = central nervous system; ACVR1 = activin A receptor type 1; ALK2 = Activin receptor-like kinase-2 is also known as Activin A receptor, type I (ACVR1); WT = wild type; ATRX-LOE = alpha thalassemia/mental retardation syndrome X-linked, loss of expression

Co-existing Genetic Mutations in Pediatric Diffuse Gliomas

A number of obligate partner mutations are frequently associated with the H3 histone alterations in pediatric HGGs (Table 1) [5, 16, 21, 49, 55–57, 64]. As for the H3 mutations themselves, these are specific to the anatomic location and also serve as potential therapeutic targets. For example, the H3.3-K27M mutation in the pons is associated with loss of function mutations in TP53 (60%) and gain-of-function mutations or amplifications in platelet-derived growth factor receptor alpha (PDGFRA; 40%) [65, 66]. The H3.1-K27M mutations in the pons are associated with recurrent gain of function somatic mutations in the activin A receptor type 1 (ACVR1; 20%) [6, 21, 56, 57]. In contrast, thalamic gliomas may undergo mitogen-activated protein kinase (MAPK) pathway activation via fibroblast growth factor receptor 1 (FGFR1) hotspot mutations or the BRAF-V600E mutation [16]. The mutations in these growth factor receptors (PDGFRA, ACVR1, and FGFR1) are not seen concurrently. Moreover, mutations in ACVR1 and FGFR1 are mutually exclusive of alterations of TP53 [64], and FGFR1 and BRAF mutations do not co-occur [16]. Hemispheric tumors harboring H3.3-G34R/V mutations are associated with TP53 mutations (100%) in conjunction with mutations in the DAXX/ATRX complex (50%) [65, 66]. These tumors also exhibit MYCN upregulation when compared with H3F3A wild-type tumors [22]. Fusion genes involving the kinase domain of the neurotrophin receptors are seen in both hemispheric and midline diffuse gliomas [21], suggesting a common pathogenic mechanism. In patients with wild-type H3F3A, a small group display mutations in isocitrate dehydrogenase-1 (3%) [37] and SET domain containing 2 (15%), which is a histone methyltransferase that catalyzes di- and trimethylation of lysine 36 on histone H3 [37, 67]. These tumors further define a class that is localized to the frontal and temporal lobes and has a relatively better prognosis. In each of these examples, the mutations that occur in conjunction with those in histone H3 are not chosen randomly and may provide a survival advantage, at least in part, by increasing the levels of mutant histone H3 in tumor cells. For example, co-occurrence of the H3.1-K27M and ACVR1 mutations (a growth factor that induces cell division) result in increased synthesis of both wild-type and mutant H3.1 proteins [11]. Similarly, the simultaneous presence of H3.3-K27M and TP53 mutations is thought to allow evasion of cell death and contribute to driving gliomagenesis [11, 50].

Mechanisms of Tumorigenesis in Pediatric Diffuse Gliomas

Through concerted research efforts, the neuro-oncology community is beginning to understand the role of histone H3 mutations in the initiation and maintenance of pediatric diffuse gliomas. The human embryonic stem-cell model of H3.3-K27M diffuse glioma established by Funato et al. [50] revealed the following salient points: 1) the K27M mutation is mitogenic in neural progenitor cells (NPCs) but not in undifferentiated embryonic stem cells or astrocytes, suggesting developmental timing and cell specificity are important determinants of their pathogenic activity; 2) histone H3 mutations alone are not sufficient to initiate tumors in vivo and require cooperating mutations (i.e., PDGFRA overexpression and TP53 attenuation)—notably, NPCs with these 3 genetic alterations (P5K cells) give rise to slow growing tumors in vivo that display low-grade histology (lack of necrosis and angiogenesis), supporting that additional mutations or cellular context enable HGG development; 3) the histone mutations upregulate the expression of stem cell-related genes (LIN28B, PLAG1, and PLAGL1) and knockdown of these genes inhibits tumor cell proliferation in vitro, suggesting that the K27M mutation acts partly by promoting de-differentiation of NPCs to a more primitive stem-cell state [50, 68]. To this end, Lewis et al. [69] demonstrated that H3K27M is a gain-of-function mutation that inhibits EZH2 methyltransferase activity resulting in a global reduction in H3K27 di- (H3K27me2) and tri-methylation (H3K27me3). Nevertheless, Chan et al. [70] showed that a subset of genes exhibited elevated H3K27me3 and EZH2 occupancy in the presence of H3K27M mutations, together driving transcriptional reprogramming and cancer development. In contrast to the global effects of H3K27M mutations, G34R/V mutant tumors only show reduced H3K36me2/me3 on nucleosomes bearing these mutations and do not affect total cellular levels of H3K36me2/me3 [22, 70]. This leads to discrete changes in gene expression that suppress differentiation (i.e., downregulation of OLIG1/2) and promote growth through upregulation of proto-oncogenes (i.e., MYCN) implicated in pediatric HGGs [5, 22, 71].

Potential Epigenetic/Genetic Therapies in Pediatric Diffuse Gliomas

Epigenetic mutations in combination with obligate genetic alterations drive the formation and maintenance of pediatric diffuse gliomas. As noted, the spatial/temporal conservation of these driver mutations is clinically relevant and creates attractive therapeutic targets [11, 12]. To date, conventional cytotoxic chemotherapy either alone or in combination with RT have failed to improve clinical outcome in diffuse midline gliomas in children (reviewed in [72]). Therefore, there is an urgent need for innovative biologically driven (with biopsy-proven molecular targets) clinical trials that use targeted therapies in combination with conventional treatments [73]. Disruption of epigenetic regulation is the cornerstone of pediatric HGGs and these epigenetic modifications can be reversed by epigenetic-based therapies.

Epigenetic Targets

Erasers (Histone Demethylases)

The gain-of-function H3K27M mutations leads to inactivation of polycomb repressive complex 2 (PRC2) methyltransferase and results in global hypomethylation of H3K27 and transcriptional derepression of potential oncogenes [69]. Hashizume et al. [38] hypothesized that inhibition of H3 demethylation and restoration of physiological H3K27 methylation could contribute to the treatment of H3.3-K27M diffuse pontine gliomas. Treatment of patient-derived H3.3-K27M mutant cell lines with the JMJD3 H3K27 histone demethylase inhibitor GSKJ4 resulted in increased H3K27 methylation (me2/me3) together with decreased cell proliferation and viability in vitro [38]. The authors also showed that specific inhibition of JDJM3 by GSKJ4 and not by UTX (ubiquitously transcribed X chromosome tetraicopeptide repeat protein) resulted in decreased proliferation and increased survival. Importantly, using the same mutant cell lines in an orthotopic murine model, the authors showed that GSKJ4 reduced tumor growth, increased animal survival, and increased levels of H3K27me3 in tumor cells. In this context, it was established that the drug crossed the BBB and was present in the brainstem. The activity of GSKJ4 appears specific to H3K27M tumors as this drug had no effect on tumors bearing wild-type H3.3 or H3.3-G34R/V mutants either in vitro or in vivo. As a result, other formulations of GSKJ4 suitable for use in humans are poised to enter clinical trials in H3 K27M-mutant diffuse midline gliomas and could be offered at diagnosis in combination with other targeted therapies and RT.

Erasers (HDACs)

The global H3 demethylation in histone H3.3-K27M mutation is associated with increased H3K27 acetylation, which may itself play a role in gliomagenesis [69, 74]. A high-throughput drug screen using patient-derived DIPG cell cultures showed substantial sensitivity to HDAC inhibitors (HDACi) [39]. Treatment with panobinostat (a pan-HDACi) showed decreased proliferation and viability of these cell cultures, which was associated with increased H3 acetylation and partial rescue of H3K27 trimethylation [39]. In vivo validation of panobinostat using a murine orthotopic patient-derived xenograft model showed increased survival and decreased tumor growth with the drug crossing the BBB. In testing for the efficacy of combination therapy, when used in conjunction with GSKJ4, panobinostat showed synergism against DIPG cell cultures in vitro [39]. Based on this promising preclinical success, panobinostat is currently offered in a phase I trial as a single agent in treatment of recurrent/progressive DIPG and HGG (PBTC-047).

Similar combinations of HDAC and demethylase inhibitors have shown preclinical activity both in vitro and in vivo in patient-derived xenografts [40]. Using a combination of vorinostat (HDACi) and tranylcypromine, a KDM1A/lysine-specific demethylase-1 inhibitor, Singh et al. [40] showed extended survival of mice in an orthotopic GBM model. In a retrospective analysis of children with HGGs (grade III–IV), valproic acid (an HDACi) in combination with chemoradiotherapy was well tolerated and sometimes demonstrated better clinical responses [75]. However, abundant caution should be exercised when selecting candidate drugs for combination use in epigenetic therapy as seen by the emergence of MGMT resistance when TMZ and vorinostat were combined [76]. In this case, vorinostat treatment of a TMZ-sensitive GBM cell line resulted in increased H3K9ac, decreased H3K9me2, and upregulation of MGMT to confer acquired TMZ resistance [76].

Writers (Histone Methyltransferases)

In a human embryonic stem cell model of H3.3-K27M gliomas, Funato et al. [50] carried out a drug screen with compounds targeting epigenetic regulators and discovered menin inhibitor 2 (MI-2) as their top hit. Menin inhibitor 2 treatment of NPC-P5K cells resulted in decreased proliferation and astrocytic differentiation in vitro, and was associated with decreased tumor growth in vivo using an orthotopic tumor model [50]. Menin (encoded by MEN1) is a member of the trithorax family histone methyltransferase complex and acts as an oncogenic cofactor in MLL-mediated leukemogenesis [51]. Current models suggest that blocking menin–MLL interactions disrupts MLL-mediated histone methylation and may therefore help in the treatment of H3.3-K27M mutant and hemispheric tumors [21, 51, 52].

Readers (Bromodomain Inhibitors)

Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that bind to acetylated lysine residues in histone tails and regulate biological processes that include DNA damage repair, DNA replication, and transcriptional regulation. The H3.3-K27M mutation causes increased H3K27ac and increased occupancy of the bromodomain-containing proteins bromodomain (BRD) containing 1 and bromodomain containing 4 in the mutant nucleosomes [74]. Additionally, inhibition of bromodomain containing 4 using the BET inhibitor JQ1 in c-Myc- or MYCN-amplified tumors blocked MYCN-related transcription [23] and c-Myc downregulation [24]. Therefore, BET inhibitors could be especially useful in the H3.3-G34R/V tumors when there is MYCN upregulation, and when used in combination with panobinostat (HDACi), could synergize and prevent resistance in H3.3-K27M tumors [41]. Although MYCN is not considered to be a direct druggable target owing to its biochemical structure (there is no ligand binding site), small-molecule targeting of proteins (i.e., checkpoint kinase 1 and aurora kinase A) that stabilize MYCN levels provides a novel therapeutic strategy in the treatment of G34R/V tumors (Table 1) [22].

Isocitrate Dehydrogenase Mutant HGGs: DNA Methyl Transferase Inhibitors

Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 enzymes lead to loss of normal enzymatic activity and increased production of the oncometabolite R-2-hydroxyglutarate (R-2-HG) [77]. Excessive accumulation of R-2-HG competitively inhibits α-ketoglutarate-dependent enzymes such as histone demethylases (JMJD2A, JMJD2C, and FBXL11) and the TET 5-methylcytosine hydroxylases [77]. This R-2-HG accumulation results in increased trimethylation of multiple histone lysine residues, DNA hypermethylation resulting in the glioma CpG island methylation phenotype, and blockage of differentiation in IDH mutant gliomas [77]. In this context, targeting DNA methylation may provide therapeutic benefit. This process is carried out by DNA methyltransferases that catalyze the transfer of a methyl group from S-adenosyl-methionine to cytosine residues in DNA [78]. Notably, the DNA methyltransferases inhibitor 5-azacytidine (Vidaza) and its deoxy analog 5-aza-deoxycytidine (Decitabine) have been used in clinical trials for patients with acute myeloid leukemia and myelodysplastic syndromes [31]. Preclinical validation of both 5-azacytidine and 5-aza-deoxycytidine in IDH1 mutant gliomas showed significant reduction of flank tumor growth, glial differentiation, and reduced DNA promoter methylation [31, 32].

Genetic Targets

There are distinct genetic abnormalities associated with histone mutations that coincide with specific anatomic locations (Table 1). Activation of the receptor tyrosine kinase, phosphatidylinositol 3-kinase/Akt, and mitogen-activated protein kinase pathways by mutations in the PDGFRA, FGFR, and MET receptors (10%) are potentially actionable and could be used in combination with conventional and other targeted therapies in order to provide synergy and prevent resistance [42, 43, 53]. Presence of the BRAF-V600E mutation should be routinely tested for in diffuse gliomas of all locations owing to the availability of small-molecule inhibitors and excellent clinical responses [44–47]. The Trk family of neurotrophin receptor fusion mutations can be specifically targeted by lestaurtinib (currently used in clinical trials in acute myeloid leukemia/myelodysplastic syndromes) in combination with BET inhibitors in the treatment of infantile hemispheric tumors [25, 26]. ACVR1 mutations leading to ligand-independent signaling of the bone morphogenetic protein (BMP) pathway are almost exclusively seen in H3.1-K27M pontine tumors and without inhibitors in clinical trials [58], there are further opportunities for therapeutic development.

Summary

There has been an explosion of knowledge in the understanding of the biology of pediatric HGGs in the past decade. The identification of driver histone mutations in specific anatomic locations has led to a new clinicopathological classification of these tumors. The identification of obligate partner mutations in nonhistone genes and their interactions with histone mutations requires further elucidation. The spatial and temporal homogeneity or conservation of the histone/nonhistone mutations in both primary and metastatic tumors suggests “epigenetic addiction,” validates biopsy-guided therapy, and supports epigenetic mutations as attractive therapeutic targets. Availability of elegant preclinical models will help us to identify and validate epigenetic targets and companion therapies. Using this strategy, clinical trials with drugs that inhibit histone modifications (writers, erasers and readers) are already underway. There is also a need to evaluate the efficacy of targeted therapies upfront when used with conventional genotoxic therapies (chemotherapy and radiation) rather than in the post-treatment relapse situation. Finally, using drug combinations that inhibit multiple targets may increase efficacy, provide synergy, and possibly avoid development of resistance to therapy.

Electronic supplementary material

Below is the link to the electronic supplementary material.